|
Patent landscape, scope, and claims: |
United States Drug Patent 8,163,798: Scope, Claims, and Landscape Analysis
Summary
United States Patent 8,163,798, titled "Substituted pyrazolo[4,3-c]pyridines," was granted on April 24, 2012, to Astex Therapeutics Limited. The patent covers a class of chemical compounds and their use in treating various diseases, primarily focusing on kinase inhibition. Key claims define specific structural moieties of the pyrazolo[4,3-c]pyridine core, substituted at defined positions. The patent's landscape is characterized by significant activity in kinase inhibitor development, with numerous patents and applications targeting similar molecular scaffolds and therapeutic areas.
What is the Core Invention of Patent 8,163,798?
The core invention of U.S. Patent 8,163,798 resides in a novel class of chemical compounds, specifically substituted pyrazolo[4,3-c]pyridines. These compounds are designed to act as potent inhibitors of various kinases, enzymes crucial for cellular signaling pathways. Dysregulation of kinase activity is implicated in numerous diseases, including cancer, inflammatory disorders, and autoimmune diseases. The patent discloses a general chemical structure and provides specific examples of compounds falling within this class, demonstrating their therapeutic potential.
What are the Key Claims of Patent 8,163,798?
The patent's claims define the legal scope of protection. For U.S. Patent 8,163,798, the independent claims, particularly Claim 1, delineate the structural features of the claimed compounds.
Claim 1 outlines a compound of Formula I:
Formula I:
R1
|
R2-N
/ \
N---C--R3
/ \
C-------C--R4
|| |
N-------N
Where:
- R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, and heteroaryl.
- R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, and heteroaryl.
- R3 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, heteroaryl, cyano, nitro, amino, substituted amino, hydroxyl, alkoxy, and thioalkoxy.
- R4 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, heteroaryl, cyano, nitro, amino, substituted amino, hydroxyl, alkoxy, and thioalkoxy.
- And the pyrazolo[4,3-c]pyridine moiety is substituted at positions 1, 2, 5, and 6 as defined.
Dependent claims further narrow the scope by specifying particular substituents for R1, R2, R3, and R4, and by defining the precise attachment points and nature of further substitutions on the pyrazolo[4,3-c]pyridine core. These dependent claims provide a layered protection, covering more specific embodiments of the core invention. For instance, certain dependent claims may specify R1 as a particular substituted alkyl group or R4 as a halogen, thereby strengthening protection for specific lead compounds identified in the patent.
The patent also includes claims directed to pharmaceutical compositions containing these compounds and methods of treating diseases by administering these compounds.
What Therapeutic Applications are Covered by Patent 8,163,798?
The patent claims methods of treating a variety of conditions where aberrant kinase activity is a contributing factor. These include:
- Cancer: The primary focus, given the widespread role of kinases in oncogenesis, cell proliferation, and metastasis.
- Inflammatory diseases: Conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where inflammatory signaling pathways are overactive.
- Autoimmune diseases: Disorders where the immune system mistakenly attacks the body's own tissues.
- Viral infections: Certain viral replication cycles involve host cell kinases, making kinase inhibitors potential antiviral agents.
The patent provides in vitro and in vivo data demonstrating the inhibitory activity of selected compounds against specific kinases, such as Janus kinases (JAKs), and their efficacy in preclinical models of disease.
What is the Status of Patent 8,163,798?
United States Patent 8,163,798 was granted on April 24, 2012. As of the latest available information, it is still in force. The patent has a term of 20 years from the filing date, which was September 30, 2008. Therefore, the patent is expected to expire around September 30, 2028. This provides a limited window for market exclusivity for products directly covered by its claims.
Who is the Patent Holder and What is Their Strategy?
The assignee of U.S. Patent 8,163,798 is Astex Therapeutics Limited. Astex Therapeutics has historically focused on the discovery and development of small molecule drugs, particularly inhibitors of kinases and other protein targets relevant to cancer and other diseases. Their strategy often involves identifying novel chemical scaffolds with therapeutic potential and securing broad patent protection around these core structures.
The licensing or internal development of compounds falling under this patent would be central to Astex's commercialization strategy. They may partner with larger pharmaceutical companies for late-stage development and commercialization, or pursue independent development if their pipeline allows.
What is the Patent Landscape for Pyrazolo[4,3-c]pyridines and Kinase Inhibitors?
The patent landscape surrounding pyrazolo[4,3-c]pyridines and kinase inhibitors is highly competitive and dynamic. Numerous pharmaceutical and biotechnology companies have active patent portfolios in this area.
Key aspects of the landscape include:
- Broad Scaffold Patents: Companies often seek to patent broad classes of compounds based on a core chemical structure, like the pyrazolo[4,3-c]pyridine in 8,163,798, to secure foundational intellectual property. These patents aim to prevent competitors from developing drugs with similar molecular architectures, even if the specific substituents or therapeutic targets differ slightly.
- Specific Compound Patents: As drug discovery progresses, companies file patents on specific, optimized drug candidates that show promising efficacy and safety profiles. These patents are often more narrowly focused but provide strong protection for a particular molecule.
- Method of Use Patents: These patents claim novel uses of existing compounds or classes of compounds for treating specific diseases. They can extend market exclusivity beyond the expiry of composition of matter patents.
- Formulation Patents: Protection for specific drug formulations (e.g., extended-release tablets, injectable solutions) that enhance drug delivery, efficacy, or patient compliance.
- Process Patents: Patents covering novel and efficient methods for synthesizing the claimed compounds.
Competitors and Key Players:
Major pharmaceutical companies with significant patent filings in the kinase inhibitor space include:
- Novartis AG
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Eli Lilly and Company
- AbbVie Inc.
- AstraZeneca PLC
Biotechnology companies like Incyte Corporation, Gilead Sciences, and many smaller focused entities are also active.
Challenges and Opportunities:
- Patent Thickets: The dense nature of patents in this field can create "patent thickets," making it challenging for new entrants to navigate and develop novel therapeutics without infringing existing intellectual property.
- Freedom to Operate (FTO) Analysis: Companies pursuing kinase inhibitor research must conduct thorough FTO analyses to identify potential patent infringements and design around existing patents.
- Patent Expiry and Generic Competition: As patents expire, the market opens to generic competition, leading to price erosion and reduced profitability for originators.
- Novel Targets and Modalities: Innovation continues to drive the development of inhibitors targeting novel kinases or utilizing different therapeutic modalities (e.g., antibody-drug conjugates, protein degraders) to overcome resistance mechanisms or address unmet medical needs.
How Does Patent 8,163,798 Relate to Other Kinase Inhibitor Patents?
Patent 8,163,798, claiming substituted pyrazolo[4,3-c]pyridines as kinase inhibitors, exists within a vast ecosystem of intellectual property related to kinase inhibition. Numerous other patents describe different heterocyclic scaffolds (e.g., pyrimidines, purines, indoles, quinazolines) that also serve as the core structures for kinase inhibitors.
Comparisons and Contrasts:
- Structural Diversity: While 8,163,798 focuses on the pyrazolo[4,3-c]pyridine core, other patents cover structurally distinct classes of kinase inhibitors. For example, patents protecting imatinib (Gleevec) are based on a 2-phenylaminopyrimidine scaffold. Tofacitinib (Xeljanz) relies on a pyrrolo[2,3-d]pyrimidine core.
- Target Specificity: Kinase inhibitors are often designed to be selective for specific kinases or kinase families. Patent 8,163,798 may claim compounds effective against JAKs, for instance, while other patents might cover inhibitors of receptor tyrosine kinases (e.g., EGFR, VEGFR), cyclin-dependent kinases (CDKs), or Bruton's tyrosine kinase (BTK). The specificity of inhibition is a critical differentiator.
- Therapeutic Areas: While this patent broadly mentions cancer and inflammatory/autoimmune diseases, specific patents may be narrowly tailored to a single indication. For example, a patent might exclusively cover compounds for treating non-small cell lung cancer with a specific EGFR mutation.
- Mechanism of Action: Most small molecule kinase inhibitors are ATP-competitive inhibitors, binding to the kinase's ATP-binding pocket. However, research is also exploring allosteric inhibitors or proteolysis-targeting chimeras (PROTACs) that employ different mechanisms of action and are protected by distinct patent claims.
The presence of patent 8,163,798 necessitates careful review by any entity developing pyrazolo[4,3-c]pyridine-based compounds or similar kinase inhibitors. Freedom-to-operate analyses would need to assess potential infringement of its broad claims, as well as its potential interactions with patents covering related chemical spaces or therapeutic targets.
What are Potential Infringement Risks Associated with Patent 8,163,798?
Companies developing or marketing drugs that fall within the scope of U.S. Patent 8,163,798 face significant infringement risks.
Key areas of infringement risk include:
- Composition of Matter: Direct infringement occurs if a company manufactures, uses, sells, or imports a compound that meets all the limitations of at least one of the patent's claims, particularly Claim 1 and its dependent claims. This is the most direct form of infringement.
- Pharmaceutical Compositions: Infringement can also occur by making, using, selling, or importing a pharmaceutical composition that includes an active ingredient covered by the patent and is intended for use in treating diseases mentioned in the patent's method of use claims.
- Method of Use: Even if a company's compound is structurally distinct enough to avoid composition of matter infringement, using that compound to treat a disease specified in the patent's method of use claims could constitute infringement, especially if the compound is known or has substantial non-infringing uses.
- Induced Infringement: If a company encourages or aids another party in infringing the patent, they may be liable for induced infringement. This is common in situations where a drug substance manufacturer supplies an active pharmaceutical ingredient (API) knowing it will be used to make a patented drug.
- Contributory Infringement: This occurs when a party supplies a component that is specifically adapted for use in an infringing manner and lacks substantial non-infringing uses, and they know the component is so adapted.
Mitigation Strategies for Potential Infringement:
- Thorough Freedom-to-Operate (FTO) Analysis: Before investing heavily in R&D or commercialization, a comprehensive FTO analysis is essential to identify existing patents, including 8,163,798, that might pose a risk.
- Patentability Searches: For companies developing novel compounds, conducting patentability searches can help ensure their inventions are novel and non-obvious over existing art.
- Design Around: If a potential infringement risk is identified, efforts can be made to design around the patent's claims by modifying the chemical structure of the compound, altering the therapeutic application, or changing the manufacturing process.
- Licensing: Negotiating a license with Astex Therapeutics is an option to obtain permission to practice the patented technology.
- Patent Litigation: In some cases, a party may challenge the validity of the patent through inter partes review (IPR) at the USPTO or by defending against an infringement lawsuit.
Key Takeaways
- U.S. Patent 8,163,798 protects substituted pyrazolo[4,3-c]pyridines as kinase inhibitors, with therapeutic applications primarily in cancer and inflammatory diseases.
- The patent's claims define a specific chemical scaffold and its allowable substitutions, providing a broad foundational protection.
- The patent is held by Astex Therapeutics Limited and is set to expire around September 30, 2028.
- The kinase inhibitor patent landscape is crowded, with numerous players and overlapping intellectual property, necessitating careful FTO analysis.
- Companies operating in this space face risks of infringing composition of matter, composition, or method of use claims.
Frequently Asked Questions
-
What specific kinases are targeted by the compounds claimed in Patent 8,163,798?
The patent abstract and specification indicate that the compounds are inhibitors of various kinases, with specific examples demonstrating activity against Janus kinases (JAKs). However, the claims are broad enough to encompass inhibitors of other kinase families depending on the specific substituents.
-
When does Patent 8,163,798 expire, and what happens after expiry?
The patent was granted on April 24, 2012, and has a term of 20 years from its filing date of September 30, 2008. It is expected to expire around September 30, 2028. After expiry, the claimed compounds and their uses enter the public domain, allowing for generic competition or the development of similar compounds without licensing requirements.
-
Can a company develop a pyrazolo[4,3-c]pyridine compound for a different therapeutic area than those explicitly mentioned in the patent without infringing?
If the compound itself falls within the scope of the patent's composition of matter claims, developing it for any use, including a different therapeutic area, would still constitute infringement. However, if the compound is structurally distinct and does not meet the claim limitations, or if the patent's method of use claims are narrowly construed, a different therapeutic application might offer a pathway to avoid infringement. A detailed FTO analysis is required.
-
What is the significance of the general Formula I in Claim 1 of Patent 8,163,798?
Formula I represents the broadest scope of the invention as claimed. It defines a generic chemical structure with variable substituents (R1, R2, R3, R4) at specific positions on the pyrazolo[4,3-c]pyridine core. Any compound that fits this formula and its accompanying definitions is considered an embodiment of the invention, subject to any further limitations in dependent claims.
-
How can a company ascertain if its drug candidate infringes Patent 8,163,798?
A comprehensive freedom-to-operate (FTO) analysis conducted by patent counsel is the standard method. This involves comparing the chemical structure of the drug candidate, its proposed formulation, and its intended therapeutic use against the precise language and scope of each claim in Patent 8,163,798.
Citations
[1] Astex Therapeutics Limited. (2012). U.S. Patent No. 8,163,798. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
